Home > Research > Publications & Outputs > SARS-CoV-2 enzyme-linked immunosorbent assays a...

Links

Text available via DOI:

View graph of relations

SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests

Research output: Contribution to Journal/MagazineJournal articlepeer-review

E-pub ahead of print

Standard

SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests. / Kay, Grant A.; Owen, Sophie I.; Giorgi, Emanuele et al.
In: Scientific Reports, Vol. 12, No. 1, 3351, 01.03.2022.

Research output: Contribution to Journal/MagazineJournal articlepeer-review

Harvard

Kay, GA, Owen, SI, Giorgi, E, Clark, DJ, Williams, CT, Menzies, S, Cuevas, LE, Davies, BMO, Eckersley, NM, Hughes, GL, Kirwan, DE, Krishna, S, Patterson, EI, Planche, T, Staines, HM & Adams, ER 2022, 'SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests', Scientific Reports, vol. 12, no. 1, 3351. https://doi.org/10.1038/s41598-022-07263-8

APA

Kay, G. A., Owen, S. I., Giorgi, E., Clark, D. J., Williams, C. T., Menzies, S., Cuevas, L. E., Davies, B. M. O., Eckersley, N. M., Hughes, G. L., Kirwan, D. E., Krishna, S., Patterson, E. I., Planche, T., Staines, H. M., & Adams, E. R. (2022). SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests. Scientific Reports, 12(1), Article 3351. Advance online publication. https://doi.org/10.1038/s41598-022-07263-8

Vancouver

Kay GA, Owen SI, Giorgi E, Clark DJ, Williams CT, Menzies S et al. SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests. Scientific Reports. 2022 Mar 1;12(1):3351. Epub 2022 Mar 1. doi: 10.1038/s41598-022-07263-8

Author

Kay, Grant A. ; Owen, Sophie I. ; Giorgi, Emanuele et al. / SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests. In: Scientific Reports. 2022 ; Vol. 12, No. 1.

Bibtex

@article{61db3ed90b4e47d39fdf6d173bb3b4fe,
title = "SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests",
abstract = "Abstract: Severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread globally since its emergence in 2019. Most SARS-CoV-2 infections generate immune responses leading to rising levels of immunoglobulins (Ig) M, A and G which can be detected using diagnostic tests including enzyme-linked immunosorbent assays (ELISA). Whilst implying previous SARS-CoV-2 infection, the detection of Ig by ELISA does not guarantee the presence of neutralising antibodies (NAb) that can prevent the virus infecting cells. Plaque reduction neutralisation tests (PRNT) detect NAb, but are not amenable to mass testing as they take several days and require use of SARS-CoV-2 in high biocontainment laboratories. We evaluated the ability of IgG and IgM ELISAs targeting SARS-CoV-2 spike subunit 1 receptor binding domain (S1-RBD), and spike subunit 2 (S2) and nucleocapsid protein (NP), at predicting the presence and magnitude of NAb determined by PRNT. IgG S2 + NP ELISA was 96.8% [95% CI 83.8–99.9] sensitive and 88.9% [95% CI 51.8–99.7] specific at predicting the presence of NAbs (PRNT80 > 1:40). IgG and IgM S1-RBD ELISAs correlated with PRNT titre, with higher ELISA results increasing the likelihood of a robust neutralising response. The IgM S1-RBD assay can be used as a rapid, high throughput test to approximate the magnitude of NAb titre.",
keywords = "Article, /692/53/2421, /692/699/255/2514, /631/326/596/4130, /631/250/2152/2153/1291, article",
author = "Kay, {Grant A.} and Owen, {Sophie I.} and Emanuele Giorgi and Clark, {David J.} and Williams, {Christopher T.} and Stefanie Menzies and Cuevas, {Luis E.} and Davies, {Benedict M. O.} and Eckersley, {Nicholas M.} and Hughes, {Grant L.} and Kirwan, {Daniela E.} and Sanjeev Krishna and Patterson, {Edward I.} and Tim Planche and Staines, {Henry M.} and Adams, {Emily R.}",
year = "2022",
month = mar,
day = "1",
doi = "10.1038/s41598-022-07263-8",
language = "English",
volume = "12",
journal = "Scientific Reports",
issn = "2045-2322",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - SARS-CoV-2 enzyme-linked immunosorbent assays as proxies for plaque reduction neutralisation tests

AU - Kay, Grant A.

AU - Owen, Sophie I.

AU - Giorgi, Emanuele

AU - Clark, David J.

AU - Williams, Christopher T.

AU - Menzies, Stefanie

AU - Cuevas, Luis E.

AU - Davies, Benedict M. O.

AU - Eckersley, Nicholas M.

AU - Hughes, Grant L.

AU - Kirwan, Daniela E.

AU - Krishna, Sanjeev

AU - Patterson, Edward I.

AU - Planche, Tim

AU - Staines, Henry M.

AU - Adams, Emily R.

PY - 2022/3/1

Y1 - 2022/3/1

N2 - Abstract: Severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread globally since its emergence in 2019. Most SARS-CoV-2 infections generate immune responses leading to rising levels of immunoglobulins (Ig) M, A and G which can be detected using diagnostic tests including enzyme-linked immunosorbent assays (ELISA). Whilst implying previous SARS-CoV-2 infection, the detection of Ig by ELISA does not guarantee the presence of neutralising antibodies (NAb) that can prevent the virus infecting cells. Plaque reduction neutralisation tests (PRNT) detect NAb, but are not amenable to mass testing as they take several days and require use of SARS-CoV-2 in high biocontainment laboratories. We evaluated the ability of IgG and IgM ELISAs targeting SARS-CoV-2 spike subunit 1 receptor binding domain (S1-RBD), and spike subunit 2 (S2) and nucleocapsid protein (NP), at predicting the presence and magnitude of NAb determined by PRNT. IgG S2 + NP ELISA was 96.8% [95% CI 83.8–99.9] sensitive and 88.9% [95% CI 51.8–99.7] specific at predicting the presence of NAbs (PRNT80 > 1:40). IgG and IgM S1-RBD ELISAs correlated with PRNT titre, with higher ELISA results increasing the likelihood of a robust neutralising response. The IgM S1-RBD assay can be used as a rapid, high throughput test to approximate the magnitude of NAb titre.

AB - Abstract: Severe acute respiratory coronavirus 2 (SARS-CoV-2) has spread globally since its emergence in 2019. Most SARS-CoV-2 infections generate immune responses leading to rising levels of immunoglobulins (Ig) M, A and G which can be detected using diagnostic tests including enzyme-linked immunosorbent assays (ELISA). Whilst implying previous SARS-CoV-2 infection, the detection of Ig by ELISA does not guarantee the presence of neutralising antibodies (NAb) that can prevent the virus infecting cells. Plaque reduction neutralisation tests (PRNT) detect NAb, but are not amenable to mass testing as they take several days and require use of SARS-CoV-2 in high biocontainment laboratories. We evaluated the ability of IgG and IgM ELISAs targeting SARS-CoV-2 spike subunit 1 receptor binding domain (S1-RBD), and spike subunit 2 (S2) and nucleocapsid protein (NP), at predicting the presence and magnitude of NAb determined by PRNT. IgG S2 + NP ELISA was 96.8% [95% CI 83.8–99.9] sensitive and 88.9% [95% CI 51.8–99.7] specific at predicting the presence of NAbs (PRNT80 > 1:40). IgG and IgM S1-RBD ELISAs correlated with PRNT titre, with higher ELISA results increasing the likelihood of a robust neutralising response. The IgM S1-RBD assay can be used as a rapid, high throughput test to approximate the magnitude of NAb titre.

KW - Article

KW - /692/53/2421

KW - /692/699/255/2514

KW - /631/326/596/4130

KW - /631/250/2152/2153/1291

KW - article

U2 - 10.1038/s41598-022-07263-8

DO - 10.1038/s41598-022-07263-8

M3 - Journal article

VL - 12

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 3351

ER -